Mckesson Corp (MCK)
Health Care · Health Care Distributors · US stock · S&P 500 component
$1,004.84
▲ +6.20 (0.62%)
Fair valueOvervalued
$658 −34.5% to fair value
$329fair band $395–$921$987
Day's range
$999.27 – $1,014.99
52-week range
$722.11 – $1,014.99
Red flags⚠ Negative equity
About Mckesson Corp
McKesson is a health care distribution company. It buys medicines and medical supplies from manufacturers and delivers them to pharmacies, hospitals, clinics and physician offices, and it also provides pharmacy technology, oncology services and related support. Revenue comes from the sale of pharmaceuticals and supplies, which carries a low percentage margin on very large volumes, with additional earnings from services and technology products.
Sales reached $411.0 billion in the last twelve months, having grown 13.4% a year over the past three years. Operating profit equals 1.6% of revenue. Return on invested capital is 1640%. Net debt is 0.7 times of EBITDA. It pays a dividend, and the yield is 0.3%. Overall, the X-Ray Score is 61 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $722.11 – $1,014.99Volume 621,300Daily, split-adjusted
Vitals
Market cap$119.8B
52-week range$722.11 – $1,014.99
Volume (last day)621,300
P/E (TTM)26.9
EBIT / EV yield5.2%
Free-cash-flow yield5.4%
Dividend yield0.3%
Revenue (TTM)$411.0B
Net income (TTM)$4.6B
Operating margin1.6%
Return on capital1,640.1%
Debt incl. leases$9.7B
Cash & securities$5.2B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$658model spread $658 – $658
Overvalued
−34.5% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Multiples use through-the-cycle earnings (0.48x of the last twelve months)
Peak-cycle earnings: the current operating margin is more than 1.5x its 7-year average, so the fair value range is widened
Price $1,005
Undervalued < $395Fair $395 – $921Overvalued > $921
10-year DCF (market-scaled) · excluded
$3,389
Peer multiples
$569
Earnings power floor (not blended)
$402
Fundamentals-adjusted multiple
$747
Growth the price implies
8.6%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
50/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield5.2%
Free-cash-flow yield5.4%
Fair value vs price0.7×
Growth
Strong
73/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)13.4%
EPS growth (3y)15.3%
Growth consistency100%
Profitability
Fair
54/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital1,640.1%
Operating margin1.6%
Gross profitability16.9%
Financial health
Weak
45/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score6 / 9
Net debt / EBITDA0.7×
Interest cover23.6×
Dividends
Fair
55/100
Dividend is typical for its sector.
See the numbers →
Dividend yield0.3%
Dividends vs free cash flow6%
Dividend growth9.3%
Quarterly results: last 6 quarters
+18.9%
Mar '25
+23.4%
Jun '25
+10.1%
Sep '25
+11.4%
Dec '25
+6.0%
Mar '26
+7.7%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $105.4B, diluted EPS $5.15.
Compare with peers
CAH Cardinal Health Inc52 COR Cencora, Inc.49 HSIC Henry Schein Inc42Other Health Care Distributors companies by X-Ray Score.
Fundamentals checklist
● 6 Good · ● 4 Average · ● 6 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldAverage
Risk models
Altman Z''Bad
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Average
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAGood
Interest coverAverage
Valuation
Fair value vs priceBad
EBIT / EV yieldGood
Profitability
Return on invested capitalGood
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 51/100.
Financials
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Revenue | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Operating income | $2.0B | $4.4B | $3.9B | $4.4B | $6.2B |
| Net income | $1.1B | $3.6B | $3.0B | $3.3B | $4.8B |
| Operating cash flow | $4.4B | $5.2B | $4.3B | $6.1B | $6.2B |
| Operating margin | 0.8% | 1.6% | 1.3% | 1.2% | 1.5% |
| Free cash flow | $4.0B | $4.8B | $3.9B | $5.5B | $5.7B |
| Diluted EPS | $7.23 | $25.03 | $22.39 | $25.72 | $38.38 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
12 bullish · 0 neutral · 4 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 951.4 | Bullish |
| EMA 10 | 957.1 | Bullish |
| SMA 20 | 914.2 | Bullish |
| EMA 20 | 931.2 | Bullish |
| SMA 50 | 896.1 | Bullish |
| EMA 50 | 897.7 | Bullish |
| SMA 100 | 846.3 | Bullish |
| EMA 100 | 870.9 | Bullish |
| SMA 200 | 852.6 | Bullish |
| EMA 200 | 842.5 | Bullish |
Oscillators (daily)
| RSI (14) | 75.74 | Bearish |
| MACD (12, 26) | 28.07 | Bullish |
| Momentum (12) | 17.69 | Bullish |
| Stochastic %K (14) | 93.95 | Bearish |
| Williams %R (14) | -6.05 | Bearish |
| CCI (20) | 170.3 | Bearish |
Pivot points (classic, last session)
S3 982.0 | S2 990.6 | S1 997.7 | Pivot 1,006.4 | R1 1,013.5 | R2 1,022.1 | R3 1,029.2 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
3.40 USD
Yield on today's price
0.34%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 1 Sep 2026 | 0.9400 |
| 1 Jun 2026 | 0.8200 |
| 2 Mar 2026 | 0.8200 |
| 1 Dec 2025 | 0.8200 |
| 2 Sep 2025 | 0.8200 |
| 2 Jun 2025 | 0.7100 |
| 3 Mar 2025 | 0.7100 |
| 2 Dec 2024 | 0.7100 |
| 30 Aug 2024 | 0.7100 |
| 3 Jun 2024 | 0.6200 |
| 29 Feb 2024 | 0.6200 |
| 30 Nov 2023 | 0.6200 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
MCK SEC filings
6 Oct 2026
8-KSEC EDGAR
Regulation FD disclosure
28 Aug 2026
8-KSEC EDGAR
Regulation FD disclosure
5 Aug 2026
10-QSEC EDGAR
Quarterly report
5 Aug 2026
8-KSEC EDGAR
Results of operations
24 Jul 2026
8-KSEC EDGAR
Shareholder vote results
1 Jul 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
12 Jun 2026
DEF 14ASEC EDGAR
Proxy statement
12 Jun 2026
8-KSEC EDGAR
Entered a material agreement
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.